📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Long-term outcomes of alemtuzumab-based reduced-intensity conditioned hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia secondary to myelodysplastic syndrome. (2014)

First Author: Potter VT

Attributed to: MRC Centre for Transplantation funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.bbmt.2013.10.021

PubMed Identifier: 24216184

Publication URI: http://europepmc.org/abstract/MED/24216184

Type: Journal Article/Review

Volume: 20

Parent Publication: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation

Issue: 1

ISSN: 1083-8791